No Data
CSPC Innovation Pharmaceutical Swings to Q1 Loss
CSPC Innovation Pharmaceutical: 2025 First Quarter Report
CSPC Innovation Pharmaceutical (300765.SZ): A net loss of 26.9 million yuan in the first quarter.
On April 23, Gelonghui reported that CSPC Innovation Pharmaceutical (300765.SZ) announced its first-quarter report, with revenue of 0.47 billion yuan, a year-on-year decrease of 9.94%, a net loss of 26.9 million yuan, a non-recurring net loss of 30.636 million yuan, and an EPS of -0.0192 yuan.
CSPC Innovation Pharmaceutical (SZSE:300765) Investors Are up 6.5% in the Past Week, but Earnings Have Declined Over the Last Three Years
CSPC Innovation Pharmaceutical (300765.SZ): The subsidiary SYS6041 antibody-drug conjugate has received approval for clinical trials in the USA.
On April 14, Gelonghui reported that CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary, CSPC PHARMA Jushi Biopharmaceutical Co., Ltd. (referred to as "Jushi Biopharmaceutical"), recently received a notification from the USA Food and Drug Administration (referred to as "FDA") that the clinical trial application for the injectable drug SYS6041 submitted by Jushi Biopharmaceutical has been approved by the USA FDA, allowing clinical trials to be conducted in the USA. SYS6041 is a monoclonal antibody conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins, thereby killing tumor cells. This time
CSPC Innovation Pharmaceutical (300765.SZ): Enlansumab injection and omalizumab for injection have begun commercial sales.
Gelonghui, April 14 - CSPC Innovation Pharmaceutical (300765.SZ) recently stated in an investor relations activity that Enlansumab injection and omalizumab injection have begun commercial sales, and the market development work is progressing in an orderly manner.